Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.260
-0.020 (-0.88%)
At close: Dec 5, 2025, 4:00 PM EST
2.261
+0.001 (0.05%)
After-hours: Dec 5, 2025, 4:18 PM EST
Spero Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Dec '25 Dec 5, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 127 | 56 | 78 | 90 | 518 | 527 | |
| Market Cap Growth | 101.47% | -27.92% | -13.02% | -82.69% | -1.83% | 186.63% | |
| Enterprise Value | 82 | -16 | -10 | 46 | 401 | 408 | |
| Last Close Price | 2.26 | 1.03 | 1.47 | 1.73 | 16.01 | 19.39 | |
| PE Ratio | - | - | 3.42 | - | - | - | |
| PS Ratio | 3.10 | 1.17 | 0.75 | 1.67 | 28.35 | 56.50 | |
| PB Ratio | 4.80 | 1.22 | 0.73 | 1.18 | 5.86 | 3.99 | |
| P/TBV Ratio | 4.81 | 1.22 | 0.73 | 1.18 | 5.86 | 3.99 | |
| EV/Sales Ratio | 2.02 | - | - | 0.86 | 21.98 | 43.73 | |
| Debt / Equity Ratio | 0.13 | 0.09 | 0.05 | 0.09 | 0.63 | 0.06 | |
| Debt / EBITDA Ratio | - | - | 0.19 | - | - | - | |
| Asset Turnover | 0.43 | 0.33 | 0.68 | 0.36 | 0.11 | 0.07 | |
| Quick Ratio | 3.74 | 2.15 | 3.42 | 5.09 | 7.98 | 9.28 | |
| Current Ratio | 3.83 | 2.19 | 3.53 | 5.25 | 8.46 | 9.70 | |
| Return on Equity (ROE) | -95.30% | -89.62% | 24.95% | -56.53% | -81.47% | -75.77% | |
| Return on Assets (ROA) | -29.77% | -30.93% | 10.90% | -12.91% | -33.88% | -38.10% | |
| Return on Capital (ROIC) | -56.38% | -55.63% | 17.17% | -16.86% | -38.73% | -44.95% | |
| Return on Capital Employed (ROCE) | -111.30% | -117.90% | 18.40% | -29.60% | -57.70% | -56.90% | |
| Earnings Yield | -34.43% | -122.10% | 29.27% | -51.82% | -17.34% | -14.85% | |
| FCF Yield | -21.73% | -41.75% | -42.35% | -8.63% | -12.43% | -16.32% | |
| Buyback Yield / Dilution | -2.96% | -1.98% | -40.98% | -21.65% | -38.01% | -23.27% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.